Litigation Details for Walgreen CO v. Novartis Pharmaceuticals Corporation (S.D.N.Y. 2018)
✉ Email this page to a colleague
Walgreen CO v. Novartis Pharmaceuticals Corporation (S.D.N.Y. 2018)
Docket | ⤷ Try a Trial | Date Filed | 2018-10-25 |
Court | District Court, S.D. New York | Date Terminated | |
Cause | 15:15 Antitrust Litigation | Assigned To | Alvin K. Hellerstein |
Jury Demand | Referred To | ||
Patents | 6,294,197; 6,395,728 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Walgreen CO v. Novartis Pharmaceuticals Corporation
Details for Walgreen CO v. Novartis Pharmaceuticals Corporation (S.D.N.Y. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2018-10-25 | 1 | Complaint | 5,399,578 (the ‘578 Patent); U.S. Patent No. 6,294,197 (the ‘197 Patent); and U.S. Patent No. 6,395,728 (the…for Exforge: the ‘578 Patent, the ‘197 Patent, and the ‘728 Patent. The ‘578 Patent, which disclosed and… the ’728 Patent, and is therefore prior art to the ‘728 Patent. The ‘904 Prior Art Patent is titled …below) to three patents that Novartis had listed in the FDA’s “Orange Book”: U.S. Patent No. 5,399,578 …the ‘728 Patent). Par and Synthon filed paragraph III certifications to the ‘578 Patent, agreeing that | External link to document |
2019-08-15 | 37 | Memorandum & Opinion | of certain follow-on patents (U.S. Patent Nos. 6,294,197 ("the '197 Patent") and 6,395,728…Novartis' patents. Novartis owned U.S. Patent No. 5,399,578 ("the '578 patent), which covered…, 4, 77. The validity of this patent was not challenged. The patent expired on March 21, 20_12, and… to the patent holder, among others, and describe the basis for its position that the patent at issue…, "Novartis"), nearing the end of one patent covering their prescription drug, Exforge, a blood | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |